Sergio Traversa, CEO of Relmada Therapeutics ($RLMD), made eight open market purchases of company shares over the past year, totaling $1.07 million. His most recent buy occurred on December 15, 2025. These purchases rank him 463rd among 4,983 insiders in our database by total amount bought, below the average of $1.46 million across 3.29 transactions per insider. Traversa reported no open market sales in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 12, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | A | Stock Appreciation Rights | 1198000 | $0.00 | 1,198,000.0000 | 33,191,622 | 9999.99% | 3.61% |
| Dec. 15, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 27500 | $4.12 | 1,300,000.0000 | 33,191,622 | 2.16% | 0.08% |
| Nov. 5, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 272500 | $2.20 | 1,272,500.0000 | 33,191,622 | 27.25% | 0.82% |
| Aug. 26, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 80545 | $0.62 | 814,569.0000 | 33,191,622 | 10.97% | 0.24% |
| Aug. 28, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 55976 | $0.74 | 1,000,000.0000 | 33,191,622 | 5.93% | 0.17% |
| Aug. 27, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 129455 | $0.67 | 944,024.0000 | 33,191,622 | 15.89% | 0.39% |
| June 26, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | A | Stock Option (right to buy) | 800000 | $0.00 | 800,000.0000 | 30,408,890 | 9999.99% | 2.63% |
| May 20, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 147686 | $0.56 | 734,024.0000 | 30,408,890 | 25.19% | 0.49% |
| May 16, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 172314 | $0.45 | 556,338.0000 | 30,408,890 | 44.87% | 0.57% |
| May 19, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 30000 | $0.50 | 586,338.0000 | 30,408,890 | 5.39% | 0.10% |
| Sept. 11, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 51407 | $2.99 | 384,024.0000 | 30,174,202 | 15.46% | 0.17% |
| Sept. 10, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 33014 | $2.75 | 332,617.0000 | 30,174,202 | 11.02% | 0.11% |
| Sept. 9, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 55579 | $2.71 | 299,603.0000 | 30,174,202 | 22.78% | 0.18% |
| May 24, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | J | Stock Option (right to buy) | 122358 | $0.00 | 183,881.0000 | 30,132,170 | 39.96% | 0.41% |
| May 24, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | A | Stock Option (right to buy) | 122358 | $0.00 | 306,239.0000 | 30,132,170 | 66.54% | 0.41% |
| Jan. 29, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 31541 | $3.71 | 175,565.0000 | 30,099,203 | 21.90% | 0.10% |
| Jan. 30, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 40999 | $3.90 | 216,564.0000 | 30,099,203 | 23.35% | 0.14% |
| Jan. 31, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | TRAVERSA SERGIO | Chief Executive Officer | P | Common Stock | 27460 | $4.00 | 244,024.0000 | 30,099,203 | 12.68% | 0.09% |